Next Article in Journal
Integrated Component Optimization and Energy Management for Plug-In Hybrid Electric Buses
Previous Article in Journal
Thermal Analysis of Nigerian Oil Palm Biomass with Sachet-Water Plastic Wastes for Sustainable Production of Biofuel
Previous Article in Special Issue
Do Bioreactor Designs with More Efficient Oxygen Supply to Ovarian Cortical Tissue Fragments Enhance Follicle Viability and Growth In Vitro?
Article Menu

Export Article

Open AccessFeature PaperReview

Recombinant Proteins for Industrial versus Pharmaceutical Purposes: A Review of Process and Pricing

1
Department of Pediatrics, Division of Hematology/Oncology, Saint Louis University School of Medicine, St. Louis, MO 63104, USA
2
Swiss Federal Institute of Technology, Lausanne (EPFL), 1015 Lausanne, Switzerland
*
Author to whom correspondence should be addressed.
Processes 2019, 7(8), 476; https://doi.org/10.3390/pr7080476
Received: 27 June 2019 / Revised: 20 July 2019 / Accepted: 22 July 2019 / Published: 24 July 2019
(This article belongs to the Special Issue Feature Review Papers)
  |  
PDF [470 KB, uploaded 24 July 2019]
  |  

Abstract

Recombinant proteins have been produced for over 30 years. Applications range from enzymes used in laundry detergents to antigen-detecting antibodies in cancer therapy. Despite similarities in manufacturing, drastic differences in retail pricing between recombinant proteins used for industrial (non-medical) versus pharmaceutical purposes exist. Industrial proteins often have a retail price in the tens of dollars per kilogram while recombinant proteins for medical use may cost billions of dollars per kilogram. This manuscript will briefly review manufacturing techniques and contrast the differences between industrial versus pharmaceutical production. Maximizing manufacturing technologies to reduce cost-of-goods (CoG) is desirable. However, the major reason for the very high pricing of pharma protein products does not reflect CoG, but the financial obligations of clinical trials, research and development, patent constraints, marketing, and return on investment. View Full-Text
Keywords: recombinant proteins; manufactured materials; drug preparation; price recombinant proteins; manufactured materials; drug preparation; price
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Puetz, J.; Wurm, F.M. Recombinant Proteins for Industrial versus Pharmaceutical Purposes: A Review of Process and Pricing. Processes 2019, 7, 476.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Processes EISSN 2227-9717 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top